Domov › Myelodysplastické syndrómy › North Carolina
Klinické štúdie Myelodysplastické syndrómy v štáte North Carolina
19 štúdií pre Myelodysplastické syndrómy hľadá účastníkov v zariadeniach v štáte North Carolina.
Mestá v štáte North Carolina
Oficiálny text štúdie (anglicky)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- a 5 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT05564390Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Duke University Medical Center, Durham
- East Carolina University, Greenville
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06484062Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health Care Institute, Winston-Salem
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- a 4 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health-Cancer Institute, Winston-Salem
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 8. 2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Duke Cancer Institute, Durham
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
Prebieha náborFáza 1/2
Vek 16 a viac · Všetky pohlavia · Aktualizované 20. 7. 2026 · NCT07155226Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- a 4 ďalších
Prebieha náborObservačná štúdia
Vek 65 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT01137825A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Prebieha náborObservačná štúdia
Vek 18 až 120 · Všetky pohlavia · Aktualizované 13. 4. 2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 24. 3. 2026 · NCT04988555CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 1. 2026 · NCT05143996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Prebieha náborObservačná štúdia
Vek 18 až 120 · Všetky pohlavia · Aktualizované 27. 10. 2025 · NCT01137643Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.